دورية أكاديمية
أعرض في EDS

A bispecific glycopeptide spatiotemporally regulates tumor microenvironment for inhibiting bladder cancer recurrence.

التفاصيل البيبلوغرافية
العنوان: A bispecific glycopeptide spatiotemporally regulates tumor microenvironment for inhibiting bladder cancer recurrence.
المؤلفون: An HW; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.; Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China., Hou DY; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.; Department of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin 150001, China.; NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, Harbin Medical University, Harbin 150001, China., Yang J; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.; Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China., Wang ZQ; Department of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin 150001, China.; NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, Harbin Medical University, Harbin 150001, China., Wang MD; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.; Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China., Zheng R; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.; Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China., Zhang NY; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.; Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China., Hu XJ; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China., Wang ZJ; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.; Department of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin 150001, China.; NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, Harbin Medical University, Harbin 150001, China., Wang L; Department of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin 150001, China.; NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, Harbin Medical University, Harbin 150001, China., Liu D; Core Facility for Protein Research, Institute of Boiphysics, Chinese Academy of Science, Beijing, China., Hao JF; Core Facility for Protein Research, Institute of Boiphysics, Chinese Academy of Science, Beijing, China., Xu W; Department of Urology, The Fourth Hospital of Harbin Medical University, Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin 150001, China.; NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, Harbin Medical University, Harbin 150001, China., Zhao Y; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.; Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China.; Core Facility for Protein Research, Institute of Boiphysics, Chinese Academy of Science, Beijing, China., Wang H; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.; Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China.
المصدر: Science advances [Sci Adv] 2023 Mar; Vol. 9 (9), pp. eabq8225. Date of Electronic Publication: 2023 Mar 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101653440 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2375-2548 (Electronic) Linking ISSN: 23752548 NLM ISO Abbreviation: Sci Adv Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : American Association for the Advancement of Science, [2015]-
مواضيع طبية MeSH: Tumor Microenvironment* , Urinary Bladder Neoplasms*, Humans ; BCG Vaccine ; CD8-Positive T-Lymphocytes ; Neoplasm Recurrence, Local ; Glycopeptides
مستخلص: Up to 75% of bladder cancer patients suffer from recurrence due to postoperative tumor implantation. However, clinically used Bacillus Calmette-Guerin (BCG) treatment failed to inhibit the recurrence. Here, we report a bispecific glycopeptide (bsGP) that simultaneously targets CD206 on tumor-associated macrophages (TAMs) and CXCR4 on tumor cells. bsGP repolarizes protumoral M2-like TAMs to antitumor M1-like that mediated cytotoxicity and T cell recruitment. Meanwhile, bsGP is cleaved by the MMP-2 enzyme to form nanostructure for the long-term inhibition of CXCR4 downstream signaling, resulting in reduced tumor metastasis and promoted T cell infiltration. In orthotopic bladder tumor models, bsGP reduced the postoperative recurrence rate to 22%. In parallel, the recurrence rates of 89 and 78% were treated by doxycycline and BCG used in clinic, respectively. Mechanistic studies reveal that bsGP reduces the matrix microenvironment barrier, increasing the spatially redirected CD8 + T cells to tumor cells. We envision that bis-targeting CD206 and CXCR4 may pave the way to inhibit tumor metastasis and recurrence.
References: Mol Imaging. 2017 Jan 1;16:1536012116689499. (PMID: 28654380)
Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):10455-10460. (PMID: 28900008)
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. (PMID: 24277834)
Nat Biomed Eng. 2021 Dec;5(12):1411-1425. (PMID: 34873307)
Chem Rev. 2002 Feb;102(2):555-78. (PMID: 11841254)
J Gene Med. 2009 Sep;11(9):772-81. (PMID: 19562713)
Int J Urol. 2006 Jun;13(6):686-91. (PMID: 16834643)
Nat Biomed Eng. 2018 Aug;2(8):611-621. (PMID: 31015634)
Angew Chem Int Ed Engl. 2022 Apr 25;61(18):e202116893. (PMID: 35181975)
Expert Rev Anticancer Ther. 2020 Nov;20(11):965-983. (PMID: 32915676)
ACS Cent Sci. 2020 Jul 22;6(7):1208-1222. (PMID: 32724855)
JAMA. 2020 Nov 17;324(19):1980-1991. (PMID: 33201207)
J Clin Pathol. 2011 Dec;64(12):1078-82. (PMID: 21693565)
Eur Urol. 2019 Nov;76(5):639-657. (PMID: 31443960)
Nat Nanotechnol. 2020 Feb;15(2):145-153. (PMID: 31988501)
Int J Cancer. 2005 Mar 20;114(2):182-9. (PMID: 15540205)
BJU Int. 2020 Feb;125(2):197-205. (PMID: 31597003)
Eur Urol. 2020 Oct;78(4):533-537. (PMID: 32684305)
Nat Rev Drug Discov. 2018 Dec;17(12):887-904. (PMID: 30361552)
ACS Nano. 2020 Jan 28;14(1):927-936. (PMID: 31927974)
World J Oncol. 2019 Jun;10(3):123-131. (PMID: 31312279)
Chem Soc Rev. 2017 May 9;46(9):2421-2436. (PMID: 28357433)
Oncol Rep. 2018 Sep;40(3):1666-1674. (PMID: 30015971)
Ann R Coll Surg Engl. 2010 Sep;92(6):519-24. (PMID: 20522307)
Chem Soc Rev. 2018 Oct 1;47(19):7401-7425. (PMID: 30175827)
Curr Drug Metab. 2019;20(6):416-429. (PMID: 30227814)
Nat Rev Cancer. 2004 Jul;4(7):540-50. (PMID: 15229479)
Eur Urol Focus. 2020 Jul 15;6(4):639-641. (PMID: 32451316)
Eur Urol. 2005 Jan;47(1):111-7. (PMID: 15582259)
Cell. 2017 May 4;169(4):750-765.e17. (PMID: 28475900)
Biomaterials. 2022 May;284:121523. (PMID: 35462306)
J Am Chem Soc. 2019 May 8;141(18):7235-7239. (PMID: 31010287)
Front Immunol. 2020 Sep 10;11:558169. (PMID: 33013928)
Nat Commun. 2019 Oct 24;10(1):4861. (PMID: 31649241)
Nat Commun. 2021 Jan 19;12(1):440. (PMID: 33469052)
Nat Rev Cancer. 2010 Jan;10(1):9-22. (PMID: 20029421)
Clin Cancer Res. 2010 Jun 1;16(11):2927-31. (PMID: 20484021)
Bioact Mater. 2021 Dec 17;14:110-119. (PMID: 35310363)
Nature. 2021 Jul;595(7868):578-584. (PMID: 34135508)
المشرفين على المادة: 0 (BCG Vaccine)
0 (Glycopeptides)
تواريخ الأحداث: Date Created: 20230301 Date Completed: 20230303 Latest Revision: 20230307
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9977173
DOI: 10.1126/sciadv.abq8225
PMID: 36857458
قاعدة البيانات: MEDLINE
الوصف
تدمد:2375-2548
DOI:10.1126/sciadv.abq8225